New Treatments Offer Hope for Post-Acute COVID-19 Vaccine Syndrome (PACVS) Sufferers
Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 09, 2025 1 hour, 45 minutes ago
Medical News: Therapeutic Advances Bring Relief for Those Battling Long Term Effects After COVID-19 Vaccination
As more people come forward reporting debilitating symptoms long after receiving COVID-19 vaccines, a growing body of research is finally shedding light on Post-Acute COVID-19 Vaccination Syndrome (PACVS). This emerging condition, experienced by a small but significant portion of vaccinated individuals, is marked by persistent fatigue, brain fog, muscle pain, and post-exertional malaise—symptoms that eerily mirror long COVID. Now, researchers from the Open Source Medicine Foundation in Estonia and the Independent Medical Alliance in Washington DC are exploring promising treatment options based on metabolic modulation and mitochondrial repair. This
Medical News report explores their findings in detail.
New research highlights effective metabolic therapies to treat post-vaccine fatigue and brain fog
Understanding the Roots of PACVS
According to the study, PACVS is likely triggered by persistent SARS-CoV-2 spike protein lingering in tissues even years after vaccination. This spike protein appears to wreak havoc on the body’s energy-producing mitochondria. It alters how cells metabolize fats and amino acids, reduces oxygen delivery due to microclots, and disrupts cellular repair mechanisms like autophagy and mitophagy. As a result, patients suffer chronic inflammation and energy failure, resulting in overwhelming fatigue, brain fog, and exercise intolerance.
Muscle studies in long COVID patients have revealed reduced mitochondrial density, a shift toward fast-twitch muscle fibers, and increased lactate production during exercise—all signs of an energy system pushed to its limits. These abnormalities are now being found in PACVS as well, providing clear biological markers for diagnosis and potential treatment targets.
Therapies Focused on Mitochondria and Metabolism
Rather than relying on general anti-inflammatory drugs or symptom suppressants, the study emphasizes targeted therapies that aim to restore cellular energy, support vascular function, and regulate oxidative stress. The review outlines several key therapeutic agents—many of which are readily available supplements—that can help alleviate symptoms by improving mitochondrial and metabolic function.
Key Therapeutic Agents and How They Work
-L-Arginine: Boosts nitric oxide production, improving blood vessel function and enhancing oxygen delivery. It also regulates immune responses in chronic viral conditions.
-Sarcosine: An amino acid derivative linked to mood and cognition, sarcosine is depleted in PACVS. Supplementation has shown benefits in psychiatric symptoms and may aid in reducing brain fog and fatigue.
-Serine: Essential for mitochondrial health, serine supports redox balance and protects against oxidative damage. Low levels are linked to psychiatric sym
ptoms and fatigue.
-L-Citrulline: Enhances nitric oxide production, improves mitochondrial energy generation, and reduces oxidative stress. Also aids in exercise performance and muscle endurance.
-L-Carnitine: Critical for transporting fatty acids into mitochondria for energy production. It also acts as an antioxidant and has shown promise in reducing fatigue and inflammation.
-Taurine: Helps stabilize calcium levels in muscle cells, protects against oxidative stress, and reduces inflammation. It is essential for proper mitochondrial and muscular function.
-Nicotinamide Mononucleotide (NMN): A precursor to NAD+, NMN helps restore mitochondrial function and improve energy levels. NAD+ levels are often depleted in PACVS.
-Creatine: Known for boosting muscle strength, creatine also supports brain energy metabolism and reduces fatigue. It enhances mitochondrial performance and phosphocreatine storage.
-Vitamin C: Functions as an antioxidant and supports mitochondrial function. It stabilizes membranes and may promote mitochondrial biogenesis, although research is ongoing.
-N-Acetylcysteine (NAC): A precursor to glutathione, NAC aids in detoxification, reduces oxidative stress, and helps stabilize the spike protein conformation. It is also thought to assist in recycling other antioxidants.
Synergy and Safety of Supplement Protocols
Many of these agents act synergistically. For example, vitamin C and NAC enhance glutathione recycling, while serine and taurine support both structural and metabolic mitochondrial stability. Creatine, NMN, and L-carnitine contribute to energy reserve replenishment and mitochondrial repair. The study warns, however, that while most supplements are generally safe, they must be taken in appropriate doses. Mild side effects like gastrointestinal discomfort can occur, and interactions with other medications—especially psychiatric drugs—should be monitored.
Why Metabolic Repair Is Crucial in PACVS
At the core of PACVS is mitochondrial dysfunction combined with ongoing oxidative stress. Mitochondria, the energy engines of our cells, are damaged by spike protein exposure, leading to impaired fat oxidation, amino acid depletion, and inflammation. Without intervention, this can spiral into a cycle of chronic fatigue and neurological decline.
Clinical and preclinical studies consistently show the spike protein disrupts mitochondrial membrane potential, increases harmful reactive oxygen species, and hampers cellular repair mechanisms. As a result, therapies that restore NAD+ levels, replenish amino acids, and support mitochondrial biogenesis have become essential tools in PACVS management.
What the Future Holds for PACVS Treatment
The researchers urge more investment in clinical trials to validate these therapeutic protocols. Key future directions include identifying metabolic biomarkers to stratify PACVS patients, personalizing treatments based on amino acid and mitochondrial profiling, and testing combination therapies for synergistic effects. Multi-omics approaches—integrating genomics, metabolomics, and proteomics—may pave the way for truly individualized care.
However, challenges remain. PACVS is not yet widely recognized in mainstream medical practice, and the variability in patient response complicates treatment standardization. Moreover, it remains difficult to determine the extent to which lingering spike protein, immune dysregulation, or other post-vaccine mechanisms drive these symptoms.
Conclusion
Post-Acute Vaccination Syndrome is an emerging, multi-system disorder that affects a small yet growing number of individuals following COVID-19 vaccination. The research conducted by the Open Source Medicine Foundation and the Independent Medical Alliance shows that PACVS is not merely psychological or imaginary—it has identifiable biological markers and real physiological consequences. By targeting mitochondrial dysfunction, oxidative stress, and vascular injury with a range of metabolic and nutritional therapies, patients may finally find relief from the long and frustrating struggle of PACVS. While more clinical studies are needed, the findings offer a promising roadmap for managing this complex syndrome and restoring quality of life to those affected.
The study findings were published in the peer reviewed journal: Biomedicine & Pharmacotherapy.
https://www.sciencedirect.com/science/article/pii/S0753332225010583
For the latest on Post-Acute Vaccination Syndrome or PACVS, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/vaccine-news
https://www.thailandmedical.news/articles/coronavirus
Share
Tweet
Share
